You can buy or sell Zogenix and other stocks, options, ETFs, and crypto commission-free!
Zogenix, Inc. Common Stock, also called Zogenix, is a pharmaceutical compan. Read More It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Zogenix
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered ...
Simply Wall StMar 8
Is Zogenix, Inc.’s (NASDAQ:ZGNX) CEO Salary Justified?
Steve Farr became the CEO of Zogenix, Inc. (NASDAQ:ZGNX) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a snap shot of the business growth. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This method should give us information to assess how appropriately the company pays the CEO. View our latest analysis for Zogenix How Does Steve Farr’s Compensation ...
Yahoo FinanceMar 6
Research Report Identifies Zogenix, LivePerson, Valmont Industries, Carnival, Inphi, and Westlake Chemical Partners LP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Zogenix, Inc.
Expected May 9, After Hours